Sign In
Buy FUSN
$13.26
+0 (+0%)
At Close: Sep 04, 2020
Wedbush Weighs in on Fusion Pharmaceuticals Inc.s Q4 2021 Earnings (NASDAQ:FUSN)
07:36am, Sunday, 14'th Nov 2021 Transcript Daily
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Investment analysts at Wedbush boosted their Q4 2021 earnings estimates for shares of Fusion Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 9th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.50) per share for the quarter, up from their []
Fusion Pharmaceuticals To Present At The 2021 Jefferies London Healthcare Conference
04:15pm, Thursday, 11'th Nov 2021
HAMILTON , Ontario and BOSTON, Nov. 11, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals
Fusion Pharmaceuticals Appoints Mohit Rawat as President and Chief Business Officer
04:05pm, Tuesday, 28'th Sep 2021
HAMILTON, ON and BOSTON, Sept. 28, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as p
Fusion Pharmaceuticals To Present At The 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
04:10pm, Thursday, 23'rd Sep 2021
HAMILTON, ON and BOSTON, Sept. 23, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as pr
Fusion Pharmaceuticals Appoints Eric S. Hoffman, Ph.D.
08:35am, Tuesday, 21'st Sep 2021
HAMILTON, ON and BOSTON, Sept. 21, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as pr
Fusion Pharmaceuticals to Participate in Upcoming Investor Conferences
04:10pm, Thursday, 02'nd Sep 2021
HAMILTON, ON and BOSTON, Sept. 2, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as pre
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Tuesday, 31'st Aug 2021
HAMILTON, Ontario and BOSTON , Aug. 31, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as
Fusion Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Update
07:30am, Tuesday, 10'th Aug 2021
Phase 1 study of FPI-1434 progressing towards multi-dose data and recommended Phase 2 dose in 1H2022 FPI-1966 advancing to clinic HAMILTON, ON and BOSTON, Aug. 10, 2021 /PRNewswire/ -- Fusion Pharma
FUSN Stock Increases Over 10% Pre-Market: Why It Happened
08:47am, Thursday, 29'th Jul 2021
The stock price of Fusion Pharmaceuticals Inc (NASDAQ: FUSN) increased by over 10% pre-market. This is why it happened.
HAMILTON, ON and BOSTON, July 28, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as pre
FUSN Stock Price Increases Over 30% Pre-Market: Why It Happened
05:29am, Tuesday, 15'th Jun 2021
The stock price of Fusion Pharmaceuticals Inc (NASDAQ: FUSN) increased by over 30% pre-market. This is why it happened.
Product candidate FPI-1434, administered at three different dose levels, demonstrated a favorable safety profile with no drug-related serious adverse events or dose-limiting toxicity Imaging shows dru
Fusion Pharmaceuticals Appoints Isabelle Dussault, Ph.D. as Senior Vice President, Research
04:10pm, Monday, 07'th Jun 2021
HAMILTON, ON and BOSTON, June 7, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as pre
Fusion Pharmaceuticals Enters into Agreement to Build Radiopharmaceutical Manufacturing Facility
08:30am, Wednesday, 02'nd Jun 2021
HAMILTON, ON and BOSTON, June 2, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec
Fusion Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
04:05pm, Thursday, 27'th May 2021
HAMILTON, ON and BOSTON, May 27, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as pre
